Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 32702095.
- Also identified by DOI 10.1093/infdis/jiaa446 and PMC identifier 7454684.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The antiviral drug remdesivir has been shown clinically effective for treatment of COVID-19. We here demonstrate suppressive but not curative effect of remdesivir in an immunocompromised patient. A man in his fifties treated with chemoimmunotherapy for chronic lymphocytic leukemia experienced a 9-week course of COVID-19 with high fever and severe viral pneumonia. During two 10-day courses of remdesivir starting 24 and 45 days after fever onset, pneumonia and spiking fevers remitted, but relapsed after discontinuation. Kinetics of temperature, C-reactive protein, and lymphocyte counts mirrored the remitting/relapsing SARS-CoV-2 infection. Combination therapy or longer treatment duration may be needed in immunocompromised patients.
Medical subject headings
- Adenosine Monophosphate
- Alanine
- Antiviral Agents
- Betacoronavirus
- Coronavirus Infections
- Leukemia, Lymphocytic, Chronic, B-Cell
- Pneumonia, Viral
- Severe Acute Respiratory Syndrome